- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.04. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| NEWCELX Aktie jetzt für 0€ handeln | |||||
| 01.04. | NewcelX prices $1.35M equity financing | 1 | Seeking Alpha | ||
| 01.04. | NewcelX sichert sich 1,35 Mio. US-Dollar durch Privatplatzierung mit 30 % Aufschlag | 16 | Investing.com Deutsch | ||
| 01.04. | NewcelX raises $1.35M in private placement at 30% premium | 2 | Investing.com | ||
| 01.04. | NewcelX Ltd.: NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing | 3 | GlobeNewswire (USA) | ||
| 10.03. | NewcelX and Eledon partner for NCEL-101 programme | 4 | Pharmaceutical Technology | ||
| 09.03. | NewcelX Enters Strategic Collaboration With Eledon Pharma | - | RTTNews | ||
| 09.03. | NewcelX, Eledon Partner to Advance a Potential Functional Cure for Type 1 Diabetes | 1 | Contract Pharma | ||
| 09.03. | NewcelX Ltd.: NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes | 776 | PR Newswire | Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation
ZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (Nasdaq:... ► Artikel lesen | |
| 09.03. | Typ-1-Diabetes: NewcelX und Eledon starten Forschungskooperation | 1 | Investing.com Deutsch | ||
| 09.03. | NewcelX partners with Eledon on type 1 diabetes therapy | 2 | Investing.com | ||
| 09.03. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 12.02. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.01. | NewcelX Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 12.01. | NewcelX Ltd.: NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression | 617 | PR Newswire | ZURICH, Jan. 12, 2026 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine... ► Artikel lesen | |
| 12.01. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 05.01. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.12.25 | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.12.25 | NewcelX: Patent für neurologische Therapien in China veröffentlicht | 4 | Investing.com Deutsch | ||
| 11.12.25 | NewcelX patent for neurological disease treatments published in China | 2 | Investing.com |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 34,755 | -1,92 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| EVOTEC | 4,500 | -3,76 % | Evotec Aktie: 2 Euro oder 6 Euro - wohin geht es für die Biotech-Aktie? | Nach dem Absturz der Evotec Aktie an die 4-Euro-Marke läuft bei dem Biotech-Titel ein erneuter Versuch einer Bodenbildung. Die zentrale charttechnische Unterstützung hat sich diesmal im Kern bei 3,995/4... ► Artikel lesen | |
| ONCONETIX | 2,320 | +107,14 % | Onconetix, Inc.: Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson | ||
| BIONTECH | 77,55 | -1,77 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| TARSUS PHARMACEUTICALS | 71,96 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| VALNEVA | 2,585 | -4,96 % | Valneva unter massivem Druck: Warum Insider bereits still und leise verkaufen - Was Sie jetzt noch wissen müssen | ||
| KYMERA THERAPEUTICS | 87,13 | 0,00 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate | KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences WATERTOWN, Mass.... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,360 | -1,18 % | Recursion Pharmaceuticals Inc. (RXRX) Partners with Citeline to Develop AI-Powered ClinTech Platform | ||
| PALISADE BIO | 1,940 | +3,19 % | PALISADE BIO, INC. - 8-K, Current Report | ||
| ARCELLX | 114,80 | +0,01 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| REPLIMUNE | 5,082 | +0,83 % | Replimune, Inc.: Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update | WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 316,84 | -0,87 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy | Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed... ► Artikel lesen | |
| ZENTALIS PHARMACEUTICALS | 3,320 | +19,86 % | Zentalis legt 400-mg-Dosis für Studie zu Eierstockkrebs-Medikament fest | ||
| BEAM THERAPEUTICS | 25,970 | +2,04 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TANGO THERAPEUTICS | 20,725 | +3,16 % | Healthcare quant check: RLAY and TNGX lead Seeking Alpha's top picks ahead of Q1 earnings |
NEWCELX LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,070 Euro und damit -4,61 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWCELX LTD finden Sie auf Wallstreet Online.